Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. develops and commercializes medical technology for patients with cardiorenal conditions, including Aquadex SmartFlow ultrafiltration therapy for fluid removal in fluid overload. Company news commonly covers financial results, Aquadex software and product updates, patent activity for catheter technology, clinical case studies in pediatric and heart-failure care, medical-meeting participation, commercial territory expansion, and hospital-support initiatives.
Nuwellis (Nasdaq: NUWE) completed its acquisition of Rendiatech on March 17, 2026, adding automated continuous kidney function monitoring to its fluid management platform.
The deal brings real-time renal monitoring technology to complement the Aquadex SmartFlow System and aims to support earlier AKI detection and future renal analytics development.
Nuwellis (Nasdaq: NUWE) reported Q4 2025 revenue of $2.4 million, up 4% year-over-year and 9% sequentially, driven by a 208% increase in U.S. console sales and higher ASPs. Q4 gross margin rose to 68.2% from 58.4% a year earlier.
Full year 2025 revenue was $8.3 million, down 5% versus 2024. Operating loss for Q4 was about $2.4 million; full-year net loss attributable to common shareholders was $17.5 million, which included a $6.4 million non-cash warrant valuation expense. The company closed a $5.0 million private placement in January 2026, appointed a new CFO, and executed a definitive agreement to acquire Rendiatech.
Nuwellis (Nasdaq: NUWE) appointed Dr. Stuart L. Goldstein as Director of Clinical Strategy on March 5, 2026, strengthening clinical leadership for its cardiorenal and pediatric focus.
Dr. Goldstein, a noted pediatric nephrology and critical care expert, will advise on product development, evidence generation, pediatric innovation, and educational initiatives to advance precision fluid management and AKI care.
Nuwellis (Nasdaq: NUWE) appointed David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The hires add public company leadership, medical device commercialization experience and capital-markets expertise to support execution of the company’s strategic priorities.
Martin Emerson brings experience leading device companies through scaling and exits, including an acquisition by BTG, and prior leadership at an organization with over $500 million in annual revenue. David McDonald returns to the board with 25+ years in healthcare capital markets and a track record of raising nearly $200 million.
Nuwellis (Nasdaq: NUWE) will report Q4 and full-year 2025 financial results on March 10, 2026. A conference call and webcast are scheduled for 9:00 AM ET to discuss results and provide a business update.
According to Nuwellis, the live webcast and an audio archive will be available on the company Investors page, and dial-in details and conference ID NUWEQ4 are provided for listeners.
Nuwellis (Nasdaq: NUWE) announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz joins from NeueHealth, where she served as Vice President of Finance and led enterprise finance, treasury, and corporate development.
Her background includes roles at Boston Scientific and Big Four public accounting, bringing public-company healthcare and medical-technology finance experience to support Nuwellis’ next phase of growth.
Nuwellis (Nasdaq: NUWE) announced a priced-at-the-market private placement and warrant inducement expected to raise approximately $5.0 million in gross proceeds prior to fees. The transaction includes 994,537 shares (or pre-funded warrants) plus 1,989,074 private placement warrants at a combined price of $3.09.
The company agreed to a warrant inducement: certain existing warrants will be exercised to buy 623,585 shares at an amended exercise price of $3.09, and Nuwellis will issue 1,247,170 new warrants exercisable at $2.84 for five years after resale registration effectiveness. Closing is expected on or about January 30, 2026. Ladenburg Thalmann served as placement agent.
Nuwellis (Nasdaq: NUWE) entered a Securities Purchase Agreement to acquire Rendiatech Ltd. on Jan 29, 2026, expanding its cardiorenal portfolio into real-time kidney function monitoring. The move adds Rendiatech’s Clarity™ automated continuous urine-output monitoring to Nuwellis’ critical-care offerings and remains subject to customary closing conditions.
The company expects to leverage existing commercial infrastructure and clinical relationships to integrate the technology and pursue future urine-based analytics and broader kidney assessment capabilities.
Nuwellis (Nasdaq: NUWE) announced board changes effective January 21, 2026: Katharyn Field and Mika Grasso were appointed to the board, and Dave McDonald, Mike McCormick, and Dr. Maria Costanzo resigned.
The company said the resignations were not due to any disagreement with Nuwellis on operations, policies, or practices. Management thanked the departing directors and said the new directors bring financial, operational, and governance experience. Additional details are disclosed in the company’s SEC Form 8-K.
Nuwellis (Nasdaq: NUWE) announced that the U.S. Patent and Trademark Office issued a new U.S. patent tied to U.S. Patent Application No. 18/298,810 on January 6, 2026.
The patent covers advanced safety mechanisms for blood return line clamps in extracorporeal blood filtration systems, with specific relevance to pediatric extracorporeal therapy and the Vivian™ Pediatric CRRT System currently in development. Nuwellis said the invention aims to improve reliability and consistency of blood flow control, support stable system performance for small patient volumes, and strengthen the company’s pediatric intellectual property portfolio and cardio-renal strategy.